Logo image of SGLB

SIGMA LABS INC (SGLB) Stock Fundamental Analysis

NASDAQ:SGLB - Nasdaq - US8265985007 - Common Stock

1.05  +0.02 (+1.94%)

Fundamental Rating

3

SGLB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 64 industry peers in the Aerospace & Defense industry. SGLB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SGLB is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SGLB has reported negative net income.
SGLB Yearly Net Income VS EBIT VS OCF VS FCFSGLB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -2M -4M -6M -8M

1.2 Ratios

Industry RankSector Rank
ROA -76.17%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SGLB Yearly ROA, ROE, ROICSGLB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -200 -400 -600 -800

1.3 Margins

Industry RankSector Rank
OM -750.81%
PM (TTM) -721.77%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGLB Yearly Profit, Operating, Gross MarginsSGLB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -500 -1K -1.5K

More info and screens

5

2. Health

2.1 Basic Checks

SGLB has more shares outstanding than it did 1 year ago.
There is no outstanding debt for SGLB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SGLB Yearly Shares OutstandingSGLB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
SGLB Yearly Total Debt VS Total AssetsSGLB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

2.2 Solvency

SGLB has an Altman-Z score of 0.74. This is a bad value and indicates that SGLB is not financially healthy and even has some risk of bankruptcy.
SGLB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.74
ROIC/WACCN/A
WACCN/A
SGLB Yearly LT Debt VS Equity VS FCFSGLB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 11.66 indicates that SGLB has no problem at all paying its short term obligations.
SGLB has a Quick Ratio of 10.79. This indicates that SGLB is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 11.66
Quick Ratio 10.79
SGLB Yearly Current Assets VS Current LiabilitesSGLB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.61% over the past year.
The Revenue has grown by 18.10% in the past year. This is quite good.
Measured over the past years, SGLB shows a quite strong growth in Revenue. The Revenue has been growing by 11.21% on average per year.
EPS 1Y (TTM)2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
Revenue 1Y (TTM)18.1%
Revenue growth 3Y61.74%
Revenue growth 5Y11.21%
Sales Q2Q%-89.13%

3.2 Future

SGLB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.92% yearly.
The Revenue is expected to grow by 43.01% on average over the next years. This is a very strong growth
EPS Next Y-32.39%
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%
EPS Next 5Y1.92%
Revenue Next Year-52.74%
Revenue Next 2Y19.03%
Revenue Next 3Y34.08%
Revenue Next 5Y43.01%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SGLB Yearly Revenue VS EstimatesSGLB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
SGLB Yearly EPS VS EstimatesSGLB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SGLB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGLB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGLB Price Earnings VS Forward Price EarningsSGLB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.19
SGLB Per share dataSGLB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SGLB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SIGMA LABS INC

NASDAQ:SGLB (5/18/2022, 8:00:02 PM)

1.05

+0.02 (+1.94%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryAerospace & Defense
Earnings (Last)04-26 2022-04-26/amc
Earnings (Next)07-20 2022-07-20
Inst Owners0.19%
Inst Owner Change-98.05%
Ins Owners3.71%
Ins Owner Change0%
Market Cap11.03M
Analysts82.86
Price Target3.06 (191.43%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.89
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB N/A
EV/EBITDA -0.19
EPS(TTM)-0.86
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.12
BVpS1.03
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -76.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -750.81%
PM (TTM) -721.77%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.11
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.66
Quick Ratio 10.79
Altman-Z 0.74
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-133.33%
EPS Next Y-32.39%
EPS Next 2Y-10.06%
EPS Next 3Y-1.5%
EPS Next 5Y1.92%
Revenue 1Y (TTM)18.1%
Revenue growth 3Y61.74%
Revenue growth 5Y11.21%
Sales Q2Q%-89.13%
Revenue Next Year-52.74%
Revenue Next 2Y19.03%
Revenue Next 3Y34.08%
Revenue Next 5Y43.01%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A